Clinical trials · source year
25 selected, source-linked clinical trial records dated 2018. This is selective source coverage, not a complete timeline.
25 selected records.
10 connected profiles.
25 distinct public records.
Cited chronology
Pramlintide
PeptideScanner retained ClinicalTrials.gov record NCT00690235 at 2026-07-30T21:07:45.452Z. Its registry update date was 2018-11-16, and PeptideScanner's reviewed identity mapping was pramlintide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT02473809 at 2026-07-30T21:10:03.006Z. Its registry update date was 2018-09-26, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00455689 at 2026-07-30T21:10:02.989Z. Its registry update date was 2018-09-18, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Afamelanotide
PeptideScanner retained ClinicalTrials.gov record NCT03634137 at 2026-07-30T21:10:03.005Z. Its registry update date was 2018-08-16, and PeptideScanner's reviewed identity mapping was afamelanotide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00223665 at 2026-07-30T21:10:02.996Z. Its registry update date was 2018-08-07, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT03619330 at 2026-07-30T21:10:02.994Z. Its registry update date was 2018-08-07, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Linaclotide
PeptideScanner retained ClinicalTrials.gov record NCT02078323 at 2026-07-30T21:10:02.997Z. Its registry update date was 2018-07-23, and PeptideScanner's reviewed identity mapping was linaclotide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT02104739 at 2026-07-30T21:10:03.007Z. Its registry update date was 2018-07-03, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Teriparatide
PeptideScanner retained ClinicalTrials.gov record NCT00926380 at 2026-07-30T21:11:31.043Z. Its registry update date was 2018-06-29, and PeptideScanner's reviewed identity mapping was teriparatide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT02717858 at 2026-07-30T21:11:31.043Z. Its registry update date was 2018-06-28, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00002597 at 2026-07-30T21:11:31.042Z. Its registry update date was 2018-06-14, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT02064348 at 2026-07-30T21:11:31.040Z. Its registry update date was 2018-06-13, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT00004635 at 2026-07-30T21:11:31.039Z. Its registry update date was 2018-05-22, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT00845507 at 2026-07-30T21:11:31.043Z. Its registry update date was 2018-04-20, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Semaglutide
PeptideScanner retained ClinicalTrials.gov record NCT02146079 at 2026-07-30T21:11:31.042Z. Its registry update date was 2018-04-18, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗
Octreotide
PeptideScanner retained ClinicalTrials.gov record NCT00966355 at 2026-07-30T21:12:47.407Z. Its registry update date was 2018-03-19, and PeptideScanner's reviewed identity mapping was octreotide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT01046721 at 2026-07-30T21:12:47.415Z. Its registry update date was 2018-03-06, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Glucagon
PeptideScanner retained ClinicalTrials.gov record NCT01680653 at 2026-07-30T21:12:47.409Z. Its registry update date was 2018-03-05, and PeptideScanner's reviewed identity mapping was glucagon.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT01120236 at 2026-07-30T21:12:47.407Z. Its registry update date was 2018-02-26, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Linaclotide
PeptideScanner retained ClinicalTrials.gov record NCT00730171 at 2026-07-30T21:12:47.419Z. Its registry update date was 2018-02-19, and PeptideScanner's reviewed identity mapping was linaclotide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT02092597 at 2026-07-30T21:12:47.409Z. Its registry update date was 2018-02-07, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT02140983 at 2026-07-30T21:12:47.414Z. Its registry update date was 2018-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Leuprolide
PeptideScanner retained ClinicalTrials.gov record NCT01116401 at 2026-07-30T21:12:47.405Z. Its registry update date was 2018-01-23, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Liraglutide
PeptideScanner retained ClinicalTrials.gov record NCT01272219 at 2026-07-30T21:12:47.414Z. Its registry update date was 2018-01-19, and PeptideScanner's reviewed identity mapping was liraglutide.
Source: ClinicalTrials.gov ↗
Exenatide
PeptideScanner retained ClinicalTrials.gov record NCT00845182 at 2026-07-30T21:12:47.410Z. Its registry update date was 2018-01-18, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗